Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...

Boehringer Ingelheim and SoundTalks end their partnership, but what does this mean for pig farmers? Find out about the future ...

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties.

the white paper underscores a widespread crisis of underappreciation, operational strain and burnout, directly impacting the ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

"Longer follow-ups after the pandemic are needed to investigate persistent brain aging effects and their long-term ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...